×

SIMPONI |

Anticuerpo monoclonal totalmente humano, con alta afinidad y especificidad por los receptores de TNF-α.1

 

 

 

Simponi®: Tecnología Transgénica

Desarrollado utilizando tecnología transgénica, proceso diferente al utilizado en el desarrollo de otros agentes anti-TNF.1

Simponi®: Especificidad

Altamente específico para el TNF-α, pero no para TNF-ß.1

 

 

 

 

 

 

 

 

 

 

 

PERSISTENCIA EN EL TRATAMIENTO CON SIMPONI®

 

La Persistencia en el Tratamiento se basa en los criterios de: Eficacia, Seguridad, Excelente experiencia del paciente y Adherencia.

 

 

 

 

 

 

 

 

Casos reales de pacientes con Simponi®

Casos Clinicos

 


 

Casos Clínicos:

Experiencia en Centroamérica con uso de Simponi en reumatología

 

El pasado 22 de junio tuvimos la oportunidad de llevar a médicos reumatólogos de la región a nuestros consultorios virtuales, presentando casos reales de pacientes con Artritis Reumatoidea y Espondilitis Anquilosante que encontraron en Simponi una solución para tener una mejor calidad de vida. Les proporcionamos estos videos para que puedan ver el detalle de cada uno de estos casos.

 

Casos Clínicos - Módulo 1


 

 

 

Ponentes:

Dra. Violeta Rosario: Especialista en Reumatología en el Hospital Clinic de Barcelona.


Dra. Carmen Tineo: Especialista en Reumatología por el Hospital Regional Universitario Jose María Cabral y Baez.

Caso Clínico - Módulo 2


 

 

 

Ponentes:

Dr. Enrique Soriano: Especialista en Reumatología por el Hospital Italiano de Buenos Aires.

 

 

 

  • Acerca de la Eficacia Sostenida
    Remisión clínica temprana que seguirá aumentando9,12
  • Acerca del Perfil de Seguridad
    Perfil de seguridad comprobado17
  • Acerca de la Calidad
    de Vida
    Mejora significativa en la función física del paciente6

     

    Referencias:

    1. SIMPONI (golimumab) Prescribing Information.

    2. Keystone EC, et al. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results ofthe GO-FORWARD Trial. J Rheumatol. 2016 Feb;43(2):298-306.

    3. Deodhar A, et al. Golimumab administered subcutaneous every 4 weeks In ankylosing spondylitis: 5 years results ofthe GO RAISE study Ann Rheum Dis de Kavanavgh a. etal Clinical Efficacy, radiographic and safety Andings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from along-term extension of a randomized, placebo-controlled trial (the GO-REVEAL study) Ann Rheum Dis 2014 Sept;73(9):1689-94.

    4. Kavanaugh a. et al Clinical Efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from along-term extension of a randomized, placebo-controlled trial (the GO-REVEAL study) Ann Rheum Dis 2014 Sept;73(9):1689-94

    5. Dalén J, et al. Treatment persistence among patient with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumato! Int. 2016 Jul;36(7):987-95.

    6. Keystone EC, et al. Ann Rheum Dis 2013;72 (Suppl 3): 867.

    7. Genovese MC, et al. J Rheumato! 2012;39(6):1185-1191.

    8. Kavanaugh, A. et al. Golimumab, a New Human Tumor Necrosis Factor Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis. Twenty-Four -Week Efficacy and Safety Results of a randomized, placebo-controlled study. Arthritis Rheum, 2009 Apr;60(4):976-86.

    9. Keystone EC, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009 Jun;68(6):789-96.

    10. Keystone EC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52 weeks results ofthe GO FORWARD study. Ann Rheum Dis 2010;69:1129-1135.

    11. Keystone EC, et. al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years ofthe GO-FORWARD' study extension. J Rheumatol. 2013 Jul;40(7):1097-103.

    12. Keystone EC, et al. Ann Rheum Dis 2009;68(6):789-796 supplementary data (Accessed at http://ard.bmj.com/content/68/6/789/suppl/DC1 23 July 2013).

    13. inman RD, et al. Efficacy and safety of Golimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(11):3402-3412.

    14. Braun J, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012 May;71(5):661-7.33

    15. Kavanaugh A, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase 11l, randomized, placebo-con-trolled trial. Arthritis Rheum. 2012 Aug;64(8)2504-17.

    16. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitiswith golimumab treatment in the Long term Extension of a Randomized, Placebo-controlled Study (GOREVEAL). J Rheumatol Suppl. 2012 Jul;89:90-3.

    17. Kay et al. Golimumab 3 year safety update: an analysis off pooled data from the long -term extensions of randomized, double blinded, placebo- controlled trials conducted in patients with rheumatoid arthritis psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2013; 0:1-9

    18. Cohen AT, et al. Why do we need observational studies of everyday patients in the real-life setting? European Heart Journal Supplements (2015) 17 (Supplement D), D2-D8.

    19. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008,11:44-47.

    20. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. ) Manag Care Pharm. 2009;15:728-740.

    21. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2014; DOI: 10.1002/14651858.CDO0001l.pub4.

    22. Svedbom A et al. Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Preference and Adherence. 2017:11; 719—729.

    23. Curtis JR, Singh JA. The use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011; 33: 679-707.

    24. Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspec- tive. Patient Prefer Adherence. 2015;9:121-131.

    25. Persistence with golimumab in immune-mediated heumatic diseases: a systematic review ofreal-world evidence in rheumatoid arthritis, axial spondy- loarthritis, and psoriatic arthritis. Patient Preference and Adherence 2017:11

    26. Klareskog L, Gaubitz M, Rodríguez-Valverde V et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011,29:238-247.

    27. Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-721.

    28. Davis JC Jr, van der Heijde DM, Braun Jet al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67:346-352.

    29. Keystone et al. Arthritis Rheum 2008:58:3319-29.

    30. Keystone et al. Ann Rheum Dis 2014;73:2094-100.

    31. Landewe et al. Ann Rheum Dis 2014;73:39-47.

    32. Sieper J, Landewé R, Rudwaleit M et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase 11! randomized trial. Arthritis Rheumatol. 2015;67:668-677.

    33. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009:68:702-709.

    34. Sieper J, van der Heijde D, Dougados M et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:700-706.

    35. Dalén J, et al. Treatment persistence among patient with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016 Jul;36(7):987-95.

    36. Bhoi et al. Comparison of adherence and Dosing Interval of Subcutaneous anti-tnf biologics in inflammatory arthritis from a Canadian administrative database. EULAR 2016 KAB1040

    37. Santo, Semeraro A, Zuccaro C et al. Two-years survival of golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and predictors thereof in real-lfe settings. ACR 2015. Abstract 2874.

    38. Tandon N, et al. Value in Heath 2012; A45-46. ISPOR 2012 [abstract] PMS66, poster presentation.

    40. Van der Heijde D, Deodhar A, Braun J2, Mack M, Hsu B2, et al.; GO-RAISE investigators. The effect of golimumab therapy on disease activity and health-related quality oflife in patients with ankylosing spondylitis: 2-year results ofthe GO-RAISE trial. ) Rheumatol, 2014 Jun;41(6):1095-103.

    41. Protocolo Clínico e Diretrizes Terapéu?cas em Artrite Reumatoide. n*177. Setembro/2015.